文献速递心脏核医学肿瘤 PET/CT

CMR与FDG PET/CT影像表型及其与已知或疑似心肌炎患者结局的关联

CMR and FDG PET/CT Imaging Phenotypes and their Association with Outcomes in Patients with Known or Suspected Myocarditis.
PubMed 文献 · J Nucl Cardiol · 2026-09-18

本研究基于Brigham and Women's Hospital的1,646例注册数据,筛选出100例已知或疑似心肌炎患者,评估CMR与FDG PET/CT影像表型(一致/不一致)与1年MACE的关联。结果显示一致组免疫抑制治疗比例更高(31% vs 9.1%,p=0.005),校正后一致组MACE风险显著更高(aHR 3.61,95%CI 1.14-11.39,p=0.028)。

要点

  • CMR与FDG PET/CT一致组免疫抑制治疗比例显著高于不一致组(31% vs 9.1%,p=0.005)。
  • 校正模型显示一致组1年MACE风险显著增高(aHR 3.61,95%CI 1.14-11.39,p=0.028)。
  • FDG PET/CT可能为特定已知或疑似心肌炎患者提供预后价值。

核心结论

  • 在已知或疑似心肌炎患者中,CMR与FDG PET/CT一致影像表型与1年MACE风险升高独立相关(aHR 3.61,95%CI 1.14-11.39,p=0.028)。

研究设计与样本

  • 回顾性注册研究,从1,646例因已知或疑似炎症性心肌病行FDG PET/CT的患者中筛选出100例符合标准者(59±13岁,74%男性,LVEF 51±13%)。

主要发现

  • 一致组45例(61±11岁,73%男性,LVEF 50±13%),不一致组55例(57±15岁,75%男性,LVEF 52±13%)。
  • 一致组免疫抑制治疗比例显著高于不一致组(31% vs 9.1%,p=0.005)。
  • 校正模型中一致组MACE风险显著高于不一致组(aHR 3.61,95%CI 1.14-11.39,p=0.028)。

关键数值与推荐

  • 纳入标准:主要临床诊断为心肌炎(包括CMR提示心肌炎的局灶性晚期钆增强)、12个月内同时接受FDG PET/CT与CMR、组织学或FDG PET/CT无心脏或心外结节病证据。
  • 影像分类:一致定义为至少一个心肌节段在CMR上呈局灶性LGE且在PET/CT上有匹配的FDG摄取;不一致定义为无匹配节段。
  • 主要结局为1年MACE,包括心衰住院、持续性室速/室颤、室速消融、左心室辅助装置植入、心脏移植和死亡。

临床怎么用

  • 对已知或疑似心肌炎患者,可结合CMR与FDG PET/CT评估影像表型,一致表型提示短期MACE风险较高,或需更密切随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cardiac magnetic resonance imaging (CMR) is a powerful tool in evaluating myocarditis. The role of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG PET/CT) in known or suspected myocarditis remains unknown. We aimed to investigate whether FDG PET/CT adds prognostic value to CMR in patients with known or suspected myocarditis. METHODS: From a registry of 1,646 patients at Brigham and Women's Hospital who underwent FDG PET/CT for known or suspected inflammatory cardiomyopathy, we applied the following criteria: 1) had a primary clinical diagnosis of myocarditis, including focal late gadolinium enhancement suggestive of myocarditis on CMR, 2) underwent both FDG PET/CT and CMR within 12 months, and 3) had no evidence of cardiac or extracardiac sarcoidosis via histology or metabolically active extracardiac sarcoidosis via FDG PET/CT. Imaging findings were categorized as 1)'concordant' if there was at-least one matched myocardial segment with focal LGE on CMR and FDG uptake on PET/CT or 2) 'discordant' if there were no matched segments. The primary outcome was major adverse cardiovascular event (MACE), a composite of heart failure hospitalization, sustained ventricular tachycardia (VT)/ventricular fibrillation, VT ablation, left ventricular assist device placement, cardiac transplant, and death at one-year. RESULTS: We identified 100 patients (59±13 years, 74% male, LVEF 51±13%) who met inclusion criteria. Concordant imaging findings were present in 45 patients (61±11, 73% male, LVEF 50±13%) and discordant in 55 (57±15, 75% male, LVEF 52±13%). Patients in the concordant group were most likely to be treated with immunosuppression after imaging than the discordant group (31% vs 9.1% p=0.005). In an adjusted model, patients with concordant imaging findings had a higher risk of MACE than patients with discordant imaging findings (aHR: 3.61 [95% CI: 1.14, 11.39], p=0.028). CONCLUSION: FDG PET/CT may have prognostic value in select patients with known or suspected myocarditis as patients in our study with concordant CMR and FDG PET/CT findings were at increased risk of MACE in follow-up.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Rojulpote CS, Hankinson SJ, Carre S, et al. CMR and FDG PET/CT Imaging Phenotypes and their Association with Outcomes in Patients with Known or Suspected Myocarditis. J Nucl Cardiol. 2026. PMID: 42759808. doi:10.1016/j.nuclcard.2026.102968

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。